CVN424 is an orally active and selective GPR6 inverse agonist with a K i of 9.4 nM and an EC 50 of 38 nM. CVN424 is brain-penetrant and has the potential for Parkinson disease research.
性状
Solid
IC50 & Target[1][2]
Ki: 9.4 nM (GPR6)
EC50: 38 nM (GPR6)
体外研究(In Vitro)
CVN424 (Compound 6i) has 265 fold and 68 fold selectivities over GPR3 and GPR12. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. Huikai Sun, et al. First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinsons Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate. J Med Chem. 2021 Apr 16.[2]. Nicola L Brice, et al. Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease. J Pharmacol Exp Ther. 2021 Jun;377(3):407-416.
溶解度数据
In Vitro: DMSO : 62.5 mg/mL (131.99 mM; Need ultrasonic)配制储备液